drugset / Trial / NCT00054327
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 2
Completed
34 enrolled
Case Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well giving chemotherapy with or without radiation therapy followed by donor stem cell transplant works in treating patients with hematologic cancer.
Timeline
- Start
- 2000-11
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Busulfan | Small molecule | 1 mg/kg | Oral |
| Subject | Busulfan | Small molecule | 40 mg/m2 | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 45 mg/kg | Intravenous |
| Subject | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Subject | Cytarabine | Small molecule | 3 g | Intravenous |
| Subject | Etoposide | Small molecule | 60 mg/kg | — |